Does adherence to hepatitis B antiviral treatment correlate with virological response and risk of breakthrough?

Journal of Hepatology

Volumn 55, Issue 6, 2011, Pages 1468-1469

  Hilleret, Marie Noelle ^a,b   Larrat, Sylvie ^b   Stanke Labesque, Francoise ^b   Leroy, Vincent ^a  

^a INSERM   (France)

^b HÔPITAL MICHALLON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ENTECAVIR; LAMIVUDINE; TENOFOVIR;

ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; GENE MUTATION; HEALTH PROGRAM; HEPATITIS B; LETTER; PRIORITY JOURNAL; QUALITY OF LIFE; TREATMENT DURATION; TREATMENT RESPONSE; VIROLOGY;

ANTIVIRAL AGENTS; FEMALE; HEPATITIS B, CHRONIC; HUMANS; MALE; MEDICATION ADHERENCE;

EID: 81355138588     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2011.04.006     Document Type: Letter

References (4)

1. W. Chotiyaputta, C. Peterson, F.A. Ditah, D. Goodwin, and A.S. Lok Persistence and adherence to nucleos(t)ide analogue treatment for chronic hepatitis B J Hepatol 54 1 2010 12 18
2. D.R. Bangsberg, and S.G. Deeks Is average adherence to HIV antiretroviral therapy enough? J Gen Intern Med 17 10 2002 812 813
3. C.E. Golin, H. Liu, R.D. Hays, L.G. Miller, C.K. Beck, and J. Ickovics A prospective study of predictors of adherence to combination antiretroviral medication J Gen Intern Med 17 10 2002 756 765
4. Reach G. Clinique de l'observance. L'exemple des diabtes. John Libbey EUROTEXT; 2006.